Prab: CSV import

2025-02-13T03:39:51Z

CSV import

← Older revision		Revision as of 03:39, 13 February 2025
Line 1:		Line 1:
	~~'''~~PRX-03140''' is a drug that was developed by [[Epix Pharmaceuticals]] for the treatment of [[Alzheimer's disease]]. It acts as a [[5-HT4 receptor]] agonist and has been shown to improve cognitive function in animal studies, but it was discontinued in human trials due to lack of efficacy.		== PRX-03140 ==

	~~== History ==~~		[[File:PRX-03140.svg\|thumb\|right\|Chemical structure of PRX-03140]]

	PRX-03140 ~~was developed by Epix Pharmaceuticals,~~ a ~~company~~ that ~~specializes~~ in the ~~discovery~~ and ~~development of novel pharmaceuticals~~. ~~The drug was designed~~ to ~~target~~ the 5-HT4 ~~receptor, a type~~ of [[serotonin ~~receptor~~]] ~~that is involved~~ in ~~learning and memory~~.		'''PRX-03140''' is a small molecule drug candidate that has been investigated for its potential therapeutic effects in the treatment of [[Alzheimer's disease]] and other [[neurodegenerative disorders]]. It is classified as a selective [[5-HT4 receptor]] partial agonist, which means it binds to and activates the 5-HT4 subtype of [[serotonin receptors]] in the brain.

	== Mechanism of Action ==		=== Mechanism of Action ===

	PRX-03140 ~~works~~ by stimulating the 5-HT4 ~~receptor~~. ~~This receptor~~ is ~~found in high concentrations in~~ the [[~~brain~~]], particularly in ~~areas involved in learning and memory. By activating this receptor~~, ~~PRX-03140~~ is ~~thought to enhance cognitive function~~.		PRX-03140 is designed to enhance [[cholinergic neurotransmission]] by stimulating the 5-HT4 receptors. Activation of these receptors is thought to increase the release of [[acetylcholine]], a neurotransmitter that is crucial for [[memory]] and [[cognition]]. This mechanism is particularly relevant in the context of Alzheimer's disease, where there is a significant loss of cholinergic neurons and a corresponding decline in acetylcholine levels.

	== ~~Clinical Trials~~ ==		=== Potential Benefits ===

	PRX-03140 ~~underwent clinical trials for the treatment of~~ Alzheimer's disease. However, the drug was discontinued in these trials due to lack of efficacy. Despite showing promise in animal studies, PRX-03140 did not demonstrate significant improvement in cognitive function in human patients.		The potential benefits of PRX-03140 in treating Alzheimer's disease include:

	~~== See Also ==~~		* Improvement in cognitive function due to enhanced cholinergic activity.
			* Neuroprotective effects that may slow the progression of neurodegeneration.
			* Modulation of [[amyloid-beta]] production, which is implicated in the pathogenesis of Alzheimer's disease.

	* [[Alzheimer's ~~disease]]~~		=== Clinical Development ===
	* [[5-~~HT4 receptor]]~~
	* [[Epix Pharmaceuticals]]		PRX-03140 has undergone various stages of clinical trials to assess its safety, tolerability, and efficacy. Early-phase trials have focused on determining the optimal dosing regimen and evaluating the drug's pharmacokinetic and pharmacodynamic profiles.

			=== Challenges and Considerations ===

			While PRX-03140 shows promise, there are several challenges associated with its development:

	~~== References ==~~		* The complexity of Alzheimer's disease pathology, which involves multiple pathways and mechanisms.
			* The need for long-term studies to fully understand the drug's impact on disease progression.
			* Potential side effects related to serotonergic activity, such as [[gastrointestinal]] disturbances and [[cardiovascular]] effects.

	~~<references />~~		== Related Pages ==

	[[~~Category:Drugs~~]]		* [[Alzheimer's disease]]
	[[~~Category:Alzheimer's disease~~]]		* [[Neurodegenerative disorders]]
	[[~~Category:5-HT4~~ receptor ~~agonists~~]]		* [[Serotonin receptor]]
	[[~~Category:Epix Pharmaceuticals~~]]		* [[Cholinergic system]]

	~~{{stub}}~~		[[Category:Experimental drugs]]
			[[Category:Neuropharmacology]]

Prab: CSV import

2024-02-25T22:25:31Z

CSV import

New page

'''PRX-03140''' is a drug that was developed by [[Epix Pharmaceuticals]] for the treatment of [[Alzheimer's disease]]. It acts as a [[5-HT4 receptor]] agonist and has been shown to improve cognitive function in animal studies, but it was discontinued in human trials due to lack of efficacy.

== History ==

PRX-03140 was developed by Epix Pharmaceuticals, a company that specializes in the discovery and development of novel pharmaceuticals. The drug was designed to target the 5-HT4 receptor, a type of [[serotonin receptor]] that is involved in learning and memory.

== Mechanism of Action ==

PRX-03140 works by stimulating the 5-HT4 receptor. This receptor is found in high concentrations in the [[brain]], particularly in areas involved in learning and memory. By activating this receptor, PRX-03140 is thought to enhance cognitive function.

== Clinical Trials ==

PRX-03140 underwent clinical trials for the treatment of Alzheimer's disease. However, the drug was discontinued in these trials due to lack of efficacy. Despite showing promise in animal studies, PRX-03140 did not demonstrate significant improvement in cognitive function in human patients.

== See Also ==

* [[Alzheimer's disease]]
* [[5-HT4 receptor]]
* [[Epix Pharmaceuticals]]

== References ==

<references />

[[Category:Drugs]]
[[Category:Alzheimer's disease]]
[[Category:5-HT4 receptor agonists]]
[[Category:Epix Pharmaceuticals]]

{{stub}}

PRX-03140 - Revision history

Prab: CSV import

Prab: CSV import